Early detection of lung cancer plays an important role in improving the survival rates and treatment outcomes. Lung cancer often starts with silent signals that go unnoticed but slowly worsen over the…
World Lung Cancer Day: Combating the Problem of Late Detection
World Lung Cancer Day is observed on August 1 annually across the globe. It was first established in the year 2012 and is observed every year to raise awareness of lung cancer…
Psychological Distress and Lung Cancer
Lung cancer is a deadly form of cancer and is responsible for many deaths worldwide. More than two million cases of lung cancer are diagnosed annually. This increasing incidence of the disease…
How Lung Cancer Affects Quality of Life
Lung cancer remains the leading cause of cancer-related deaths worldwide. Patients with lung cancer often experience multiple symptoms associated with the disease as well as during the treatment process. The adverse effects…
Lung Cancer Risk Factors in Adults with Interstitial Lung Disease
Interesting Lung Diseases (ILDs) are characterized by pathological changes in Pulmonary parenchyma. It is a group of conditions that cause inflammation in the lungs. This can be caused by medication, radiation therapy…
Cooking Fumes and Lung Cancer – What’s the Association?
Over the past few years, lung cancer no longer remains among men only but is also on the rise among women. This is primarily due to shifts in smoking habits and environmental…
High-Dose Aumoltertinib for Untreated EGFR- Variant NSCLC
Aumoltertinib is a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and has achieved potent efficacy for advanced EGFR-mutated non-small cell lung cancer patients. Phase 2 non-randomized clinical trial was conducted at…
Taletrectinib Received FDA Approval for ROS1-Positive NSCLC
Recently, FDA has granted approval to Taletrectinib for treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer in adults. Taletrectinib has demonstrated high response rates and was well tolerated among…